£500m of new investments from life science sector announced

The Prime Minister welcomes nearly £500m of new investment from the Biopharmaceutical sector today.

The investment aims to create at least 420 high-skilled jobs and drive economic prosperity across the UK.

Also, the Prime Minister will today convene the Biopharmaceutical CEO Roundtable of global industry leaders – including AstraZeneca, GSK and Pfizer.

Prime Minister Boris Johnson said: “With scientists around the world working tirelessly to learn more about the Omicron variant, we have never been more indebted to the extraordinary power of Life Sciences.

“Today I am bringing global industry leaders together to discuss our renewed efforts against Covid-19, while ensuring we are better equipped to tackle future healthcare challenges.

“As we press ahead with our goal to become a science superpower, the new investments made today will help us forge life-changing breakthroughs against other diseases, such as cancer and dementia, while creating hundreds of high-skilled jobs across the country.”

The individual investments secured today include:

• £400m from Fujifilm Diosynth Biotechnologies to create the largest biopharmaceutical manufacturing site in the UK.

• £30m from GSK to deepen understanding of diseases such as Alzheimer’s, and improve the success and speed of R&D of new medicines using advanced technologies.

• £17m from Bristol Myers Squibb to expand their headquarters to accommodate global drug development in data science and biometrics.

• £11.7m from J&J for a new digital surgery ecosystem in Leeds;

• £1.5 million from Roche for a blood test evaluation programme that will genomically profile lung cancer.

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.